title: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
abstract: Hypersensitivity to abacavir affects about 4% of patients who receive the drug for HIV-1 infection. We did a retrospective, case-control study to identify multiple markers in the vicinity of HLA-B associated with hypersensitivity reactions. HLA-B57 was present in 39 (46%) of 84 patients versus four (4%) of 113 controls (p<0 small middle dot0001). However, because of low numbers of women and other ethnic groups enrolled, these findings relate largely to white men. The lower sensitivity of HLA-B57 for predicting hypersensitivity to abacavir identified in this study compared with a previous report highlights that predictive values for markers will vary across populations. Clinical monitoring and management of hypersensitivity reactions among patients receiving abacavir must remain unchanged.
authors.affiliation: HIV Clinical Development and Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC 27709, USA. svh31379@gsk.com
authors.forename: Seth
authors.initials: S
authors.lastname: Hetherington
authors.forename: Arlene R
authors.initials: AR
authors.lastname: Hughes
authors.forename: Michael
authors.initials: M
authors.lastname: Mosteller
authors.forename: Denise
authors.initials: D
authors.lastname: Shortino
authors.forename: Katherine L
authors.initials: KL
authors.lastname: Baker
authors.forename: William
authors.initials: W
authors.lastname: Spreen
authors.forename: Eric
authors.initials: E
authors.lastname: Lai
authors.forename: Kirstie
authors.initials: K
authors.lastname: Davies
authors.forename: Abigail
authors.initials: A
authors.lastname: Handley
authors.forename: David J
authors.initials: DJ
authors.lastname: Dow
authors.forename: Mary E
authors.initials: ME
authors.lastname: Fling
authors.forename: Michael
authors.initials: M
authors.lastname: Stocum
authors.forename: Clive
authors.initials: C
authors.lastname: Bowman
authors.forename: Linda M
authors.initials: LM
authors.lastname: Thurmond
authors.forename: Allen D
authors.initials: AD
authors.lastname: Roses
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D015224:Dideoxynucleosides / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000209:etiology / Q000235:genetics; D005260:Female; D005819:Genetic Markers; D014644:Genetic Variation; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1; D015235:HLA-B Antigens / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011237:Predictive Value of Tests; D044469:Racial Groups / Q000235:genetics; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D012680:Sensitivity and Specificity; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D005819:Genetic Markers; D015235:HLA-B Antigens; D018894:Reverse Transcriptase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D000099227:Abacavir; C103707:HLA-B57 antigen